Guardant Health (NASDAQ:GH – Get Free Report) had its price objective dropped by equities researchers at Piper Sandler from $193.00 to $190.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler‘s price target would suggest a potential upside of 19.65% from the stock’s previous close.
Several other equities analysts have also recently issued reports on the stock. BTIG Research boosted their target price on shares of Guardant Health from $195.00 to $210.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th. Sanford C. Bernstein restated an “outperform” rating and set a $210.00 price target on shares of Guardant Health in a research report on Thursday, September 10th. Stephens lifted their price objective on shares of Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. UBS Group upped their price objective on shares of Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Finally, Roth Capital assumed coverage on shares of Guardant Health in a research note on Thursday, October 22nd. They set a “buy” rating and a $200.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $190.88.
Read Our Latest Stock Report on GH
Guardant Health Stock Up 5.2%
Guardant Health stock opened at $158.79 on Tuesday. The business’s 50-day moving average price is $169.26 and its 200 day moving average price is $132.22. The firm has a market cap of $21.31 billion, a price-to-earnings ratio of -43.15 and a beta of 1.67. Guardant Health has a 52 week low of $74.55 and a 52 week high of $191.05.
Guardant Health (NASDAQ:GH – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.46. The company had revenue of $360.98 million during the quarter, compared to analyst estimates of $350.72 million. The company’s revenue was up 36.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.74) earnings per share. Equities analysts expect that Guardant Health will post -3.08 EPS for the current year.
Insider Buying and Selling at Guardant Health
In other news, CTO Darya Chudova sold 7,738 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $178.00, for a total transaction of $1,377,364.00. Following the completion of the sale, the chief technology officer owned 70,635 shares of the company’s stock, valued at $12,573,030. The trade was a 9.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Terilyn Monroe sold 46,300 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the transaction, the insider owned 22,979 shares of the company’s stock, valued at approximately $3,794,292.48. This trade represents a 66.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 99,455 shares of company stock valued at $16,752,081. Corporate insiders own 5.60% of the company’s stock.
Hedge Funds Weigh In On Guardant Health
Several hedge funds and other institutional investors have recently made changes to their positions in GH. Banco Santander S.A. purchased a new stake in shares of Guardant Health during the third quarter worth approximately $596,000. HighTower Advisors LLC lifted its holdings in Guardant Health by 1.8% in the 3rd quarter. HighTower Advisors LLC now owns 22,802 shares of the company’s stock valued at $4,067,000 after purchasing an additional 412 shares in the last quarter. Intech Investment Management LLC lifted its holdings in Guardant Health by 54.2% in the 3rd quarter. Intech Investment Management LLC now owns 15,138 shares of the company’s stock valued at $2,700,000 after purchasing an additional 5,319 shares in the last quarter. Trillium Asset Management LLC purchased a new position in Guardant Health in the 3rd quarter valued at $2,181,000. Finally, Bellwether Advisors LLC acquired a new stake in Guardant Health during the 3rd quarter worth $1,395,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring.
Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Featured Articles
- Five stocks we like better than Guardant Health
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
